Shanghai Labway Clinical Laboratory Co., Ltd.

Total Valuation

Shanghai Labway Clinical Laboratory Co., Ltd. carries a market capitalization of 3.51B, placing it among publicly traded companies globally. Its enterprise value stands at 3.50B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Shanghai Labway Clinical Laboratory Co., Ltd. currently has 400.52M shares outstanding.

Valuation Ratios

The price-to-sales ratio is 2.42, and the price-to-book ratio stands at 4.08.

Enterprise Valuation

On an enterprise value basis, Shanghai Labway Clinical Laboratory Co., Ltd. trades at an EV/EBITDA multiple of 198.28 and an EV/FCF ratio of 49.57. The EV/Sales ratio of 2.17 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 198.28 provides insight into valuation relative to core operating earnings.

Financial Position

Shanghai Labway Clinical Laboratory Co., Ltd. maintains a current ratio of 2.81, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.55, indicating elevated leverage, while an interest coverage ratio of 2.52 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Shanghai Labway Clinical Laboratory Co., Ltd. has paid 2.25M in income taxes, reflecting an effective tax rate of 57.48.

Stock Price Statistics

Shanghai Labway Clinical Laboratory Co., Ltd.'s stock has declined approximately -10% over the past 52 weeks. The 50-day moving average sits at 9.60, while the 200-day moving average is 10.08.

Income Statement

Over the trailing twelve months, Shanghai Labway Clinical Laboratory Co., Ltd. generated 1.61B in revenue and converted that into -130.82M in net income, yielding earnings per share of -0.28. EBITDA reached 17.65M, while operating income came in at 17.65M.

Balance Sheet

Shanghai Labway Clinical Laboratory Co., Ltd. holds 707.63M in cash and equivalents against 224.44M in total debt, resulting in a net debt position of -521.91M. Total book value stands at 955.81M, with working capital of 1.23B providing operational flexibility.

Cash Flow

After subtracting -63.47M in capital expenditures, free cash flow totaled -63.47M - equivalent to -0.16 per share.

Margins

Shanghai Labway Clinical Laboratory Co., Ltd. operates with a gross margin of 21.93, reflecting its pricing power and cost economics. The operating margin of 1.09 and net profit margin of -8.11 provide insight into operational efficiency.

Dividends & Yields

The company's payout ratio of -88.50 indicates the proportion of earnings distributed to shareholders.

Scores

Shanghai Labway Clinical Laboratory Co., Ltd. posts an Altman Z-Score of 4.34, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.